1Speckner A, Glykofrydes D, Ohlin M, et al. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol, 1999,80(pt8) :2183-2191.
2Marshall GS, Li M, Stout GG,et al. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol,200,13(3) :329-341.
3Gicklhom D, Eickmann M, Meyer G,et al. Differential effects of glycoprotein B epitope-spectific antibodies on human cytomegalovirus-induced cell-cell fusion.J Gen Virol,2003,84(pt7): 1859-1862.
4Lantto J, Lindroth Y, Ohlin M. Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomeglovirus.Eur J Immunol,2002,32(6): 1659-1669.
5Rothe M, Pepperl-Klindworth S, Lang D,et al. An antigen fragment encompassing the AD2 domains of glycoproetin B from two different strains is sufficient for differentiation of primary vs.recurrenthuman cytomgalovirus infection by ELiSA.J Med Virol, 2001,65(4) :719-729.
6Lantto J, Fletcher JM,Ohlin M.A divalent antibody format is required for neutralization of human cytomegaloirus vis antigenic domain 2 on glycoprotein B.J Gen Virol,2002,83(pt8) :2001-2005.
7Arizono H, Ishii S, Nagao T, et al.Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus.First communication:plasma concentration,distribution,metablolism and excretion of the new monoclonal antibody,regavirumab after intravenous administration in rats and rabbits.Arzneimittelforschung,1994,44(7): 890-898.
8Matsuzawa K,Koyama T,Sugawara S,et al.The preclinicl satfty evaluation of human monoclonal antibody against cytomegalovirus.Fundam Appl Toxicol,1992,19(1):26-32.
9Azuma J,Kurimoto T,Tsuji S,et al.Phase I study on human monoclonal antibody against cytomegalovirus:pharmacokinetics and immunogenicity.J Immunother,1991,10(4):278-285.
10Boeckh M,Bowden RA,Storer B,et al.Randomized,placebo-controlled,double-blind study of cytomegalovirus-specific monoclonal antibody)MSL-109)for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant,2001,7(6):343-351.
